NYSE
25.92USD
-0.12 (-0.46%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
147.7B
P/E
—
EPS
—
Beta
0.29
52W range
23.11-28.75
Day range
25.86–26.28
Open
26.02
Prev close
26.04
Volume
23.5M
Avg volume
36.7M
Dividend
1.72
IPO
1972-06-01
https://247wallst.com/investing/2026/06/10/prediction-pfizer-stock-will-double-on-this-date/ · 6/10/2026+0.60
https://247wallst.com/investing/2026/06/08/three-value-focused-etfs-pay-solid-dividends-and-keep-outperforming-the-market-in-2026/ · 6/9/2026+0.40
https://www.etftrends.com/watch-hidden-risks/ · 6/6/2026-0.20
https://www.marketbeat.com/instant-alerts/appian-cfo-says-ai-workflows-government-demand-are-driving-big-customer-growth-2026-06-02/ · 6/2/2026+0.10
https://www.businesswire.com/news/home/20260529645249/en/ASCO-2026-Bayer-Shares-New-Findings-for-NUBEQA%C2%AE-darolutamide-Regarding-Cognitive-Decline-in-Men-with-Advanced-Prostate-Cancer-Compared-to-Enzalutamide-in-Phase-II-ARACOG-Head-to-Head-Trial/ · 5/30/2026
https://www.cnbc.com/2026/05/29/innovent-shares-rise-10percent-after-pact-with-pfizer-of-up-to-10point5-billion.html · 5/29/2026+0.40
https://www.fool.com/investing/2026/05/22/is-relay-therapeutics-a-buy-after-promising-trial/ · 5/22/2026+0.10
https://247wallst.com/investing/2026/05/18/7-healthcare-ai-stocks-under-50-with-huge-upside-potential/ · 5/18/2026+0.10
https://247wallst.com/investing/2026/05/15/michael-burrys-latest-buys-include-a-6-66-yielding-pharma-giant-and-an-oil-stock-up-46-this-year-here-is-why/ · 5/15/2026+0.60
https://www.marketbeat.com/instant-alerts/valneva-q1-earnings-call-highlights-2026-05-13/ · 5/13/2026+0.30
https://www.fool.com/investing/2026/05/09/could-buying-this-beaten-down-healthcare-stock-mak/ · 5/9/2026-0.30
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-beats-first-quarter-profit-estimates-strong-demand-blood-thinner-eliquis-2026-05-05/ · 5/5/2026+0.80
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works